{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:20:27Z","timestamp":1789132827448,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00296-021-04969-2","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T05:07:57Z","timestamp":1629349677000},"page":"1839-1843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-2746","authenticated-orcid":false,"given":"Lydia","family":"Leonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9725-1791","authenticated-orcid":false,"given":"Christina","family":"Kalogeropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-1724","authenticated-orcid":false,"given":"Fotini","family":"Paliogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-1384","authenticated-orcid":false,"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"4969_CR1","doi-asserted-by":"crossref","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942","DOI":"10.1136\/annrheumdis-2021-220134"},{"key":"4969_CR2","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.jaut.2021.102687","volume":"123","author":"A-D Bakasis","year":"2021","unstructured":"Bakasis A-D, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE et al (2021) COVID-19 infection among autoimmune rheumatic disease patients: data from an observational study and literature review. J Autoimmun 123:102687","journal-title":"J Autoimmun"},{"key":"4969_CR3","doi-asserted-by":"crossref","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S et al (2021) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 3(6):e419\u2013e426","DOI":"10.1016\/S2665-9913(21)00059-X"},{"key":"4969_CR4","doi-asserted-by":"publisher","first-page":"135245852110262","DOI":"10.1177\/13524585211026272","volume":"2","author":"T Spelman","year":"2021","unstructured":"Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (2021) Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry. Mult Scler J 2:135245852110262","journal-title":"Mult Scler J"},{"key":"4969_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2014.01.008","volume":"48\u201349","author":"C Tani","year":"2014","unstructured":"Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M et al (2014) The diagnosis and classification of mixed connective tissue disease. J Autoimmun 48\u201349:46\u201349","journal-title":"J Autoimmun"},{"key":"4969_CR6","doi-asserted-by":"publisher","unstructured":"Aviv R, Weber A, Anzum T, Federbush M, Horowitz D, Singas E (2021) Prolonged COVID-19 disease in a patient with rheumatoid arthritis on rituximab therapy. J Infect Dis 224(3):557\u2013559. https:\/\/doi.org\/10.1093\/infdis\/jiab248","DOI":"10.1093\/infdis\/jiab248"},{"key":"4969_CR7","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1136\/annrheumdis-2020-217549","volume":"80","author":"P Guilpain","year":"2021","unstructured":"Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ et al (2021) Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis 80:E10 (BMJ Publishing Group)","journal-title":"Ann Rheum Dis"},{"key":"4969_CR8","doi-asserted-by":"crossref","unstructured":"Friedman MA, Winthrop KL (2021) Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. Ann Rheum Dis. (BMJ Publishing Group)","DOI":"10.1136\/annrheumdis-2021-220398"},{"key":"4969_CR9","doi-asserted-by":"publisher","unstructured":"Benucci M, Quartuccio L, Li Gobbi F, Damiani A, Grossi V, Infantino M et al (2020) Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al. Ann Rheum Dis https:\/\/doi.org\/10.1136\/annrheumdis-2020-218590. (BMJ Publishing Group)","DOI":"10.1136\/annrheumdis-2020-218590"},{"issue":"34","key":"4969_CR10","first-page":"185","volume":"20","author":"L Quartuccio","year":"2021","unstructured":"Quartuccio L, Treppo E, Binutti M, Del Frate G, De Vita S (2021) Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology 20(34):185\u2013191","journal-title":"Rheumatology"},{"key":"4969_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.semarthrit.2020.06.013","volume":"50","author":"J Leipe","year":"2020","unstructured":"Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W (2020) Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthr Rheum 50:1087\u20131088 (W.B. Saunders)","journal-title":"Semin Arthr Rheum"},{"key":"4969_CR12","doi-asserted-by":"crossref","unstructured":"Gerber V, Velay A, Boehn L, Solis M, Kaeuffer C, Rougier E et al (2021) Protracted SARS-CoV-2 pneumonia with rituximab treatment: about two cases. J Med Virol 93:4141\u20134144. (John Wiley and Sons Inc.)","DOI":"10.1002\/jmv.26921"},{"key":"4969_CR13","doi-asserted-by":"publisher","first-page":"108723","DOI":"10.1016\/j.clim.2021.108723","volume":"227","author":"A Kenig","year":"2021","unstructured":"Kenig A, Ishay Y, Kharouf F, Rubin L (2021) Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol 227:108723","journal-title":"Clin Immunol"},{"issue":"10","key":"4969_CR14","first-page":"001922","volume":"7","author":"P Daniel","year":"2020","unstructured":"Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad F (2020) COVID-19 in a patient treated for granulomatosis with polyangiitis: persistent viral shedding with no cytokine storm. Eur J Case Rep Intern Med 7(10):001922","journal-title":"Eur J Case Rep Intern Med"},{"key":"4969_CR15","doi-asserted-by":"publisher","unstructured":"Koff A, Laurent-Rolle M, Hsu JCC, Malinis M (2020) Prolonged incubation of SARS-CoV-2 in a patient on rituximab therapy. Infect Control Hosp Epidemiol 1\u20132. https:\/\/doi.org\/10.1017\/ice.2020.1239. (Online ahead of print)","DOI":"10.1017\/ice.2020.1239"},{"key":"4969_CR16","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","volume":"80","author":"H Schulze-Koops","year":"2021","unstructured":"Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A (2021) Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 80:e67 (BMJ Publishing Group)","journal-title":"Ann Rheum Dis"},{"key":"4969_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/annrheumdis-2020-217864","volume":"80","author":"J Avouac","year":"2021","unstructured":"Avouac J, Air\u00f3 P, Carlier N, Matucci-Cerinic M, Allanore Y (2021) Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis 80:37 (BMJ Publishing Group)","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4969_CR18","doi-asserted-by":"publisher","first-page":"e243338","DOI":"10.1136\/bcr-2021-243338","volume":"14","author":"J Vasconcelos","year":"2021","unstructured":"Vasconcelos J, Portugal R, Torres R, Falc\u00e3o S (2021) Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab. BMJ Case Rep 14(6):e243338","journal-title":"BMJ Case Rep"},{"issue":"8","key":"4969_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00296-021-04905-4","volume":"41","author":"A Rodriguez-Pla","year":"2021","unstructured":"Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ (2021) COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. Rheumatol Int 41(8):1509\u20131514","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04969-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T16:18:53Z","timestamp":1673108333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04969-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4969"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04969-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}